Literature DB >> 15221198

Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism.

K I Melkersson1, M-L Dahl, A-L Hulting.   

Abstract

RATIONALE: With the antipsychotic drugs available today, especially with some of the newer, atypical antipsychotics, metabolic side effects, such as weight gain, diabetes mellitus and lipid abnormalities, have become a complication to the drug therapy that have to be recognized and treated.
OBJECTIVE: The aim of this article is to suggest guidelines for prevention and treatment of adverse effects of antipsychotics on glucose-insulin homeostasis and lipid metabolism, whereas strategies for management of antipsychotic-induced weight gain are summarized elsewhere.
METHOD: The guidelines are based on results of experimental and clinical studies presented in the article, as well as on a recently published review of 180 articles in the field.
RESULTS: Both conventional and atypical antipsychotics can indirectly, by causing obesity, promote development of insulin resistance and type-2 diabetes. In addition, some atypical agents probably directly induce hyperinsulinemia, followed by weight gain, insulin resistance and drug-induced, sometimes insulin-dependent, diabetes.
CONCLUSION: In this article, guidelines for the management of adverse metabolic effects of antipsychotics are described.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221198     DOI: 10.1007/s00213-004-1922-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

1.  Olanzapine-induced elevation of plasma triglyceride levels.

Authors:  B B Sheitman; P M Bird; W Binz; L Akinli; C Sanchez
Journal:  Am J Psychiatry       Date:  1999-09       Impact factor: 18.112

2.  Drug-induced hyperglycemia.

Authors:  B Luna; M N Feinglos
Journal:  JAMA       Date:  2001 Oct 24-31       Impact factor: 56.272

Review 3.  Hyperglycemia and antipsychotic medications.

Authors:  D W Haupt; J W Newcomer
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

4.  Diabetes mellitus in schizophrenic patients.

Authors:  S Mukherjee; P Decina; V Bocola; F Saraceni; P L Scapicchio
Journal:  Compr Psychiatry       Date:  1996 Jan-Feb       Impact factor: 3.735

5.  Evaluation of loxapine succinate in chronic schizophrenia.

Authors:  M L Clark; W K Huber; J Sullivan; F Wood; J P Costiloe
Journal:  Dis Nerv Syst       Date:  1972-12

6.  Olanzapine increases weight and serum triglyceride levels.

Authors:  D N Osser; D M Najarian; R L Dufresne
Journal:  J Clin Psychiatry       Date:  1999-11       Impact factor: 4.384

Review 7.  Weight gain associated with neuroleptic medication: a review.

Authors:  J M Stanton
Journal:  Schizophr Bull       Date:  1995       Impact factor: 9.306

8.  Neuroleptic withdrawal in schizophrenic patients. A review of the literature.

Authors:  P L Gilbert; M J Harris; L A McAdams; D V Jeste
Journal:  Arch Gen Psychiatry       Date:  1995-03

9.  Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.

Authors:  K I Melkersson; M-L Dahl
Journal:  Psychopharmacology (Berl)       Date:  2003-07-08       Impact factor: 4.530

10.  Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Authors:  Murad Atmaca; Murat Kuloglu; Ertan Tezcan; Bilal Ustundag
Journal:  J Clin Psychiatry       Date:  2003-05       Impact factor: 4.384

View more
  14 in total

1.  A crossover study on lipid and weight changes associated with olanzapine and risperidone.

Authors:  Kuan-Pin Su; Po-Lun Wu; Carmine M Pariante
Journal:  Psychopharmacology (Berl)       Date:  2005-10-21       Impact factor: 4.530

2.  Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry.

Authors:  Dan Cohen; Saskia Huinink
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 3.  [Differences between men and women in side effects of second-generation antipsychotics].

Authors:  W Aichhorn; A B Whitworth; E M Weiss; H Hinterhuber; J Marksteiner
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

4.  Reduction in the use of potentially inappropriate drugs among old people living in geriatric care units between 2007 and 2013.

Authors:  Maria Gustafsson; Per-Olof Sandman; Stig Karlsson; Ulf Isaksson; Jörn Schneede; Maria Sjölander; Hugo Lövheim
Journal:  Eur J Clin Pharmacol       Date:  2015-02-26       Impact factor: 2.953

5.  A parametric analysis of olanzapine-induced weight gain in female rats.

Authors:  G D Cooper; L C Pickavance; J P H Wilding; J C G Halford; A J Goudie
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

Review 6.  Quality assessment of physical activity recommendations within clinical practice guidelines for the prevention and treatment of cardio-metabolic risk factors in people with schizophrenia.

Authors:  Davy Vancampfort; Kim Sweers; Michel Probst; Alex J Mitchell; Jan Knapen; Marc De Hert
Journal:  Community Ment Health J       Date:  2011-06-21

7.  Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

Authors:  Ren-Rong Wu; Jing-Ping Zhao; Zhe-Ning Liu; Jin-Guo Zhai; Xiao-Feng Guo; Wen-Bing Guo; Jing-Song Tang
Journal:  Psychopharmacology (Berl)       Date:  2006-04-07       Impact factor: 4.530

Review 8.  Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization.

Authors:  Takumi Kawaguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2010-04-28       Impact factor: 5.742

Review 9.  Drug-induced metabolic syndrome.

Authors:  Marion R Wofford; Deborah S King; T Kristopher Harrell
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-02       Impact factor: 3.738

10.  Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units.

Authors:  Maria Gustafsson; Stig Karlsson; Hugo Lövheim
Journal:  BMC Pharmacol Toxicol       Date:  2013-02-08       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.